169 related articles for article (PubMed ID: 34829999)
21. Solution structure of a two-repeat fragment of major vault protein.
Kozlov G; Vavelyuk O; Minailiuc O; Banville D; Gehring K; Ekiel I
J Mol Biol; 2006 Feb; 356(2):444-52. PubMed ID: 16373071
[TBL] [Abstract][Full Text] [Related]
22. Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies.
Yang J; Nagasawa DT; Spasic M; Amolis M; Choy W; Garcia HM; Prins RM; Liau LM; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):451-8. PubMed ID: 22748657
[TBL] [Abstract][Full Text] [Related]
23. Vaults: a ribonucleoprotein particle involved in drug resistance?
Mossink MH; van Zon A; Scheper RJ; Sonneveld P; Wiemer EA
Oncogene; 2003 Oct; 22(47):7458-67. PubMed ID: 14576851
[TBL] [Abstract][Full Text] [Related]
24. Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.
Bai H; Wang C; Qi Y; Xu J; Li N; Chen L; Jiang B; Zhu X; Zhang H; Li X; Yang Q; Ma J; Xu Y; Ben J; Chen Q
BMC Cancer; 2019 May; 19(1):454. PubMed ID: 31092229
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of major vault protein during the life cycle of the human parasite Schistosoma mansoni.
Reis EV; Pereira RV; Gomes M; Jannotti-Passos LK; Baba EH; Coelho PM; Mattos AC; Couto FF; Castro-Borges W; Guerra-Sá R
Parasitol Int; 2014 Feb; 63(1):120-6. PubMed ID: 24148287
[TBL] [Abstract][Full Text] [Related]
26. Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis.
Lötsch D; Steiner E; Holzmann K; Spiegl-Kreinecker S; Pirker C; Hlavaty J; Petznek H; Hegedus B; Garay T; Mohr T; Sommergruber W; Grusch M; Berger W
Oncotarget; 2013 Nov; 4(11):1904-18. PubMed ID: 24243798
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk between Src and major vault protein in epidermal growth factor-dependent cell signalling.
Kim E; Lee S; Mian MF; Yun SU; Song M; Yi KS; Ryu SH; Suh PG
FEBS J; 2006 Feb; 273(4):793-804. PubMed ID: 16441665
[TBL] [Abstract][Full Text] [Related]
28. Multiple human vault RNAs. Expression and association with the vault complex.
van Zon A; Mossink MH; Schoester M; Scheffer GL; Scheper RJ; Sonneveld P; Wiemer EA
J Biol Chem; 2001 Oct; 276(40):37715-21. PubMed ID: 11479319
[TBL] [Abstract][Full Text] [Related]
29. Direct activation of the human major vault protein gene by DNA-damaging agents.
Shimamoto Y; Sumizawa T; Haraguchi M; Gotanda T; Jueng HC; Furukawa T; Sakata R; Akiyama S
Oncol Rep; 2006 Mar; 15(3):645-52. PubMed ID: 16465425
[TBL] [Abstract][Full Text] [Related]
30. Vault RNAs partially induces drug resistance of human tumor cells MCF-7 by binding to the RNA/DNA-binding protein PSF and inducing oncogene GAGE6.
Chen J; OuYang H; An X; Liu S
PLoS One; 2018; 13(1):e0191325. PubMed ID: 29346433
[TBL] [Abstract][Full Text] [Related]
31. The Vault Nanoparticle: A Gigantic Ribonucleoprotein Assembly Involved in Diverse Physiological and Pathological Phenomena and an Ideal Nanovector for Drug Delivery and Therapy.
Frascotti G; Galbiati E; Mazzucchelli M; Pozzi M; Salvioni L; Vertemara J; Tortora P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572350
[TBL] [Abstract][Full Text] [Related]
32. A vault ribonucleoprotein particle exhibiting 39-fold dihedral symmetry.
Kato K; Tanaka H; Sumizawa T; Yoshimura M; Yamashita E; Iwasaki K; Tsukihara T
Acta Crystallogr D Biol Crystallogr; 2008 May; 64(Pt 5):525-31. PubMed ID: 18453688
[TBL] [Abstract][Full Text] [Related]
33. The genomic sequence of the murine major vault protein and its promoter.
Mossink M; van Zon A; Fränzel-Luiten E; Schoester M; Scheffer GL; Scheper RJ; Sonneveld P; Wiemer EA
Gene; 2002 Jul; 294(1-2):225-32. PubMed ID: 12234684
[TBL] [Abstract][Full Text] [Related]
34. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics.
Mossink MH; van Zon A; Fränzel-Luiten E; Schoester M; Kickhoefer VA; Scheffer GL; Scheper RJ; Sonneveld P; Wiemer EA
Cancer Res; 2002 Dec; 62(24):7298-304. PubMed ID: 12499273
[TBL] [Abstract][Full Text] [Related]
35. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
van Zon A; Mossink MH; Schoester M; Scheper RJ; Sonneveld P; Wiemer EA
Cancer Res; 2004 Jul; 64(14):4887-92. PubMed ID: 15256459
[TBL] [Abstract][Full Text] [Related]
36. Expression of major vault protein gene in osteosarcoma patients.
Dalla-Torre CA; de Toledo SR; Yoshimoto M; Petrilli AS; Andrade JA; Chilton-MacNeill S; Squire JA; Zielenska M
J Orthop Res; 2007 Jul; 25(7):958-63. PubMed ID: 17415755
[TBL] [Abstract][Full Text] [Related]
37. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
[TBL] [Abstract][Full Text] [Related]
38. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene.
Stein U; Bergmann S; Scheffer GL; Scheper RJ; Royer HD; Schlag PM; Walther W
Oncogene; 2005 May; 24(22):3606-18. PubMed ID: 15750632
[TBL] [Abstract][Full Text] [Related]
39. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line.
Huffman KE; Corey DR
Biochemistry; 2005 Feb; 44(7):2253-61. PubMed ID: 15709737
[TBL] [Abstract][Full Text] [Related]
40. [The structure of cellular vaults, their role in the normal cell and in the multidrug resistance of cancer].
Szaflarski W; Nowicki M; Zabel M
Postepy Biochem; 2011; 57(3):266-73. PubMed ID: 22235652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
